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Abstract
Mucosal or parenteral immunization with a killed unencapsulated pneumococcal whole cell antigen (WCA) with an adjuvant
protects mice from colonization by a TH17 CD4+ cell-mediated mechanism. Using preparative SDS gels, we separated the
soluble proteins that compose the WCA in order to identify fractions that were immunogenic and protective. We screened
these fractions for their ability to stimulate IL-17A secretion from splenocytes obtained from mice immunized with WCA and
adjuvant. We identified 12 proteins within the stimulatory fractions by mass spectrometry; these proteins were then cloned,
recombinantly expressed and purified using an Escherichia coli expression system. The ability of these proteins to induce IL-
17A secretion was then evaluated by stimulation of mouse splenocytes. Of the four most stimulatory proteins, three were
protective in a mouse pneumococcal serotype 6B colonization model. This work thus describes a method for identifying
immunogenic proteins from the soluble fraction of pneumococcus and shows that several of the proteins identified protect
mice from colonization when used as mucosal vaccines. We propose that, by providing protection against pneumococcal
colonization, one or more of these proteins may serve as components of a multivalent pneumococcal vaccine.
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Introduction
While pneumococcal conjugate vaccines (PCVs) have resulted
in significant reductions in rates of invasive pneumococcal disease
due to vaccine-serotypes, infection with Streptococcus pneumoniae
remains an important public health issue, particularly in develop-
ing countries [1]. Post-PCV-licensure surveillance of pneumococ-
cal disease also demonstrates replacement of carriage and invasive
disease serotypes with those not covered in the PCVs [2,3,4].
Additionally, the impact of PCVs on mucosal disease such as otitis
media and pneumonia has been less clear. For these reasons and
with the goal of developing a vaccine with lower cost of goods and
complexity of manufacture than PCVs, alternative approaches to
pneumococcal vaccination are a high global health priority.
Many strategies have been proposed and evaluated (reviewed
in [5]). One approach that is being actively pursued and is
currently in a Phase I trial involves the use of killed whole
pneumococcal cells. Our group has shown that either mucosal or
parenteral immunization with a killed unencapsulated pneumo-
coccal whole cell vaccine (denoted WCV when administered with
appropriate adjuvant) protects mice against pneumococcal
colonization with a clinical isolate of serotype 6B and fatal
aspiration-sepsis with isolates of serotypes 3 and 5 [6,7,8].
Perhaps due to the unencapsulated nature of the immunogen,
and in light of recent studies that reveal robust immunological
responses directed against pneumococci of diverse genotypes and
serotypes [9], immunization with WCV is expected to confer
protection against a wide variety of strains. Protection against
aspiration/sepsis is transferrable by passive transfer of sera from
immunized rabbits to mice, whereas depletion of CD4+ T cells
in immunized mice at the time of challenge results in no
detectable loss of protection, pointing to a critical role of
antibodies [7]. In contrast immunity to colonization conferred by
immunization with WCV is dependent on CD4+ T cells and IL-
17A [7]. Indeed, in the mouse model used, congenital absence of
antibodies, IFN-c or IL-4 has no effect, whereas depletion of
CD4+ T cells or congenital absence of the IL-17A receptor is
associated with loss of protection against pneumococcal coloni-
zation [10,11].
As methods for formulating the WCV preparation have been
optimized for GMP-grade and scale production, various modes of
inactivation of the parent WCV strain, RM200 (a strain derived
from the unencapsulated strain Rx1, in which the autolysin A gene
has been disrupted and the pneumolysin gene has been replaced
with one encoding for a pneumolysoid PdT [7]), have been
investigated. We have shown that inactivation methods using beta-
propiolactone or organic solvents, such as chloroform, that retain
the soluble proteins of RM200 (by avoiding the requirement for
post-inactivation washing in the original ethanol-inactivated WCA
[6]) produce significantly more potent vaccine preparations, such
that 100 times lower WCA concentration confers the same
immune and protective responses as compared to a WCA
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These data led us to explore the hypothesis that proteins with
protective potential may be present in the soluble fraction of the
WCA (released during growth or by inactivation): consistent with
this hypothesis, we also showed that intranasal immunization with
the soluble fraction of chloroform-inactivated WCA (thereby
lacking the pelleted whole cells and their contents) conferred
highly significant reductions in colonization compared with
adjuvant-alone immunized mice [8].
The identification of the protective components in the soluble
fraction of the WCA has at least two important advantages. First,
by its nature, the WCA is a highly complex preparation,
consisting of a mixture of antigens among over 2000 presumed
expressed pneumococcal proteins. For manufacturing and quality
control issues, knowledge of components of the vaccine that are
particularly relevant to protection would be very useful. Lot-to-
lot variability could be examined by determining the concentra-
tion of individual proteins among the different lots of WCA.
Secondly, currently there are several efforts aimed at the
development of novel protein-based pneumococcal protein
vaccines. The success of the pneumococcal conjugate vaccine
against invasive disease can be ascribed (at least in part) to the
remarkable impact of these vaccines on colonization: by CDC
estimates, over 2/3 of cases prevented by pneumococcal
conjugate vaccine is the result of indirect, or herd, protection
[12]. For this reason, ideally, an alternative strategy should
confer protection against both pneumococcal invasive disease
and colonization and thus the inclusion of antigens that target
pneumococcal colonization in a protein-based vaccine would be
advisable. There are many examples of pneumococcal proteins
that have been investigated as components of a protein subunit
vaccine [5], and combinations of several of those explored have
been shown to significantly reduce colonization in mice in a CD4
+ T cell- [13] and IL-17A- [14] dependent manner when used as
intranasal immunogens adjuvanted with cholera toxin. This work
aimed to identify the immunogenic and protective proteins in the
soluble fraction of an inactivated WCA preparation and evaluate
the potential of these antigens to reduce colonization when used
as recombinant protein vaccines.
Materials and Methods
Bacterial strains
The whole cell pneumococcal vaccine was prepared from strain
RM200 that is derived from a parent Rx1 strain that is autolysin-
negative, capsule-negative, and expresses a non-hemolytic pneu-
molysoid variant in the place of the hemolytic pneumolysin [8].
For this work, RM200 was grown to an OD600 of 1.0
(corresponding to approximately 6.0610
8 CFU/ml), washed in
Lactated Ringer’s solution supplemented with 10% sucrose,
concentrated to an OD600 of 32, and inactivated by mixing with
chloroform as previously described (1/40 [chloroform vol/
bacterial cell vol] for 2 hours) [8]. Chloroform-inactivated whole
cell antigen (hereafter referred to as WCC) was not washed; any
residual organic solvent was sublimated away from the preparation
during lyophilization. WCC supernatant was harvested by
centrifuging WCC rehydrated in sterile water at 16,0006g for
5 minutes and collecting the aqueous layer separate from the
pellet. Protein estimation was performed using Total Protein Kit
with bovine serum albumin as a standard (Pierce).
Animal models and ethics statement
For all experiments, 4–6 week old C57BL/6J mice from
Jackson Laboratories (Bar Harbor, ME) were used. All immu-
nizations were performed by instilling 20 ml of a mixture of PBS,
1 mg of cholera toxin (CT; List Biologicals, Campbell, CA) and
either 4 mg of the indicated purified pneumococcal protein or
100 mg of WCC as immunogens onto the nares of gently
restrained unanesthetized mice. Control animals were immu-
nized with CT mixed in PBS alone to control for any nonspecific
effect of the adjuvant alone. Animals were immunized intrana-
sally twice at one-week intervals. Spleens were harvested from
immunized animals 2–4 weeks following last immunization
(without pneumococcal challenge) for stimulations with WCC
supernatant fractions and purified pneumococcal proteins.
Immunized animals that were subsequently challenged received
an inoculum consisting of 10
7 CFU of a clinical type 6B
pneumococcal strain (0603; described in [6]) in 10 ml volume
intranasally while awake. These mice were euthanized by CO2
inhalation one week following challenge; tracheal washes were
obtained and assessed for density of pneumococcal colonization
as previously described [6]. All animal work was performed in
accordance with NIH guidelines and approved by the IACUC of
Children’s Hospital Boston and Harvard Medical School.
Molecular mass separation of WCC supernatant fractions
WCC supernatant (containing 800–900 mg of protein) was
mixed with LDS 4x sample buffer and loaded into the 8 center
lanes of a NuPAGE 4–12% Bis-Tris 12-lane gel (Invitrogen
Corporation, Carlsbad, CA) then resolved by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) for 30–
40 minutes at 200V. The preparative gel was then equilibrated in
elution buffer (2 mM phosphate buffer at pH 7.0) for three 20-
minute equilibrations. Transverse elution of the proteins through
the thickness of the preparative gel was performed at constant
300V for forty minutes (current ranged from 65–90 mAmp) in
elution buffer in a mini whole gel transverse eluter system (Bio-
Rad Laboratories, Hercules, CA). Current was reversed for
15 seconds at the end of the elution and individual fractions were
collected in fourteen chambers beneath the preparative gel and
harvested into separate tubes. The protein content of each fraction
was quantified by Total Protein Kit (Biorad).
Mass spectrometry
After determining which fractions were most immunogenic in
the IL-17A splenocyte stimulation assays described below, MS
identification of the proteins contained in the bands comprising
the most immunogenic fractions was carried out at the Taplin
Biological Mass Spectrometry Facility of Harvard Medical School,
Boston, MA.
Protein expression and purification
Gene sequences for twelve of the proteins identified from
immunogenic fractions were amplified by PCR using primers
designed from the sequence published for serotype 4 strain
TIGR4 (Table 1). Two restriction enzyme sites, BamHI and
SphI, were included in primers to allow cloning into the
expression vector pQE30 (Qiagen, Inc) which also incorporates a
6x-histidine (his) tag. PCR products were ligated into the pQE30
expression vector and ligation products were transformed into
competent Escherichia coli (XL/Blue) cells. Transformed cells were
selected by growth on LB ampicillin and the identity of the insert
confirmed by sequencing. Successfully transformed E. coli cells
were grown in 1L LB ampicillin and protein expression was
induced with 0.1 mM IPTG overnight at room temperature.
Pelleted E. coli were lysed in lysis buffer (20 mM Tris-HCl,
500 mM NaCl with lysozyme at 1 mg/ml and DNAse at 10 mg/
ml) and sonicated. Protein was purified over a column of Ni-
TH17 Antigens in Soluble Pneumococcal Fractions
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The protein-bound column was washed with lysis buffer/40 mM
imidazole, and proteins were eluted in 250 mM imidazole.
Proteins were run on SDS-PAGE under reducing conditions and
gels were Coomassie-stained to confirm protein expression and
purity. Purified proteins were desalted on a PD-10 Sephadex
column using PBS prior to use in cellular stimulation assays.
Splenocyte stimulations and ELISAs
Spleens were harvested from WCC-immunized C57BL/6 mice
and were processed as previously described into a cellular
suspension [10] and stimulated either with 1) equivalent concen-
trations of size-separated fractions of WCC supernatant or with 2)
10 mg/ml of recombinant protein. Splenocytes were incubated for
3 days; plates were then spun to pellet cells, after which the
supernatants were collected and assayed for IL-17A using a mouse
IL-17A ELISA kit (R&D Systems, Inc).
Statistical analysis
All statistical analyses were carried out using PRISM (version
4.0; GraphPad Software Inc). Colonization densities and IL-17A
values among immunization groups were compared by Mann-
Whitney U test or by the Kruskal-Wallis test with Dunn’s
correction for multiple comparisons. P values ,0.05 were
considered to represent statistical significance.
Results
Identification of stimulatory fractions by preparative SDS
PAGE
While the supernatant of WCC (WCCsup) contains approxi-
mately 15% of the total protein of freshly rehydrated noncen-
trifuged WCC, prior work has demonstrated that, with respect to
protection against pneumococcal colonization, retention of the
soluble portion of the vaccine yielded a 100-fold more potent
whole cell preparation when compared with an ethanol-inactivat-
ed preparation in which the soluble fraction was removed by serial
washings of the pellet [8]. In order to identify immunogenic
proteins within WCCsup, we proceeded to fractionate WCCsup
proteins by preparative SDS PAGE. After proteins were separated
by SDS PAGE, they were eluted from the gel by transverse elution
with recovery of approximately 50% of the loaded protein.
Fourteen fractions were generated from each transverse elution.
By evaluating SDS-PAGE of collected fractions, we confirmed
consistency of elutions across different experiments, as shown by
the similarly sized bands in fractions from elutions performed at
different times (Figure 1A). This allowed us to combine fractions
from several elutions to yield approximately 3 ml of each fraction
with concentrations ranging from 27–43 mg/ml. By SDS-PAGE, it
appeared that each fraction consisted of 2–4 predominant bands.
Fractions were all brought to the same protein concentration
and used to stimulate splenocyte suspensions obtained from WCC-
immunized mice. The WCC and WCCsup elicited median IL-
17A responses of 2100 and 3300 pg/ml respectively (Figure 1B).
The most stimulatory fractions were fractions 9 and 10, which
elicited median IL-17A values of 530 and 380 pg/ml, respectively.
These two fractions and, as a control that would allow us to
Table 1. TH17 cell antigens isolated from immunogenic fractions of soluble portion of RM200, predicted function, and primers
used for expression in E. coli.
Locus in
TIGR4 Predicted function Primer sequence (59–39) using Bam HI and SphI restriction sites
SP 0435 Elongation factor up- GCGGATCCATGATTGAAGCAAGTAAAT
down- GCGCATGCTTAGGCACGAGAAACGTAAG
SP 0516 Heat shock protein up- GCGGATCCATGGCCCAAGATATAAAAAATGAAG
down- GCGCATGCTTAGTTATACACCACTACCATT
SP 0862 Ribosomal protein S1 up- GCGGATCCATGAACGAATTTGAAGATTTGC
down- GCGCATGCTTAAAGTTCGATATCACCAAACAAATC
SP 0946 Hypothetical up- GCGGATCCATGAATACAAATCTTGCAAG
down- GCGCATGCCTAAATCAACTCTGTCCC






SP 1458 Thioredoxin reductase up- GCGGATCCATGTACGATACTATTATTATCGG
down- GCGCATGCTTAACTATGTTCTGTAATGAATT








SP 1733 Putative phosphatase up- GCGGATCCATGGAAATTTCATTATTAACAGATG
down- GCGCATGCTCATTCTGCATCCTCCTCGTTC
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were re-applied onto SDS-PAGE and the most predominant
bands within each fraction were submitted for mass spectrometry
analysis.
Bioinformatic targeting of proteins identified by mass
spectrometry
Peptides within the submitted bands were identified and
matched to the proteomic sequence of pneumococcal strain
TIGR4. Proteins with more than 2 identified peptide matches
were considered positively identified. Using these methods, 37
proteins were identified in the stimulatory fractions but not in the
non-stimulatory counterpart. The corresponding sequences of
identified proteins were analyzed bioinformatically; we prioritized
antigens that were highly conserved (.85% amino acid homology)
among the published pneumococcal sequences and with ,10%
homology to human proteins. This narrowed the panel of proteins
to 12 proteins, which we examined in more detail; these are listed
in Table 1.
Several recombinant proteins elicit IL-17A from
splenocytes
The 12 identified proteins were successfully expressed in E. coli
and purified. Gels for each of the 12 proteins demonstrated
predominant size-appropriate single bands suggesting successful
purification. Each recombinant protein was used at 10 mg/ml to
stimulate splenocytes from WCC-immunized mice. Several
individual proteins elicited robust median IL-17A responses; in
particular, SP2070, SP1534, SP0435 and SP0862 elicited the
highest median IL-17A responses (range 260–2300 pg/ml) as
shown in Figure 2. Other recombinant proteins, such as SP2092,
were clearly less stimulatory, suggesting that not all proteins
contained within bands from stimulatory fractions were contrib-
uting to the IL-17A response.
Proteins administered intranasally with cholera toxin
reduce nasopharyngeal carriage
To assess the protective efficacy of recombinant proteins, we
began with a preparation containing a mixture of the three
antigens that were most stimulatory in the splenocyte stimulations
(Figure 2) and compared the ability of this mixture vs. WCC to
elicit a TH17 response and protect against colonization. The TH17
responses following immunization with the mixture of proteins or
WCV were similar and in both cases significantly higher compared
to that of mice immunized with CT alone (p=0.0001 for both,
Figure 3A). Our experience with the WCV administered
intranasally indicates that a post-immunization IL-17A value of
$250 pg/ml elicited following whole blood stimulation with WCA
is a good predictor of protection against colonization [10].
Accordingly, animals immunized with the combination vaccine
were significantly protected from colonization (over 2 log
reduction in median density of colonization, p=0.0004 compared
with CT immunized animals), and the combination vaccine was as
protective as the WCV in this experiment, with all but one nasal
wash being free of detectable pneumococci (Figure 3B).
Having shown that a combination of these proteins protected
animals from colonization, we performed immunizations with
individual proteins to determine which proteins contributed most
to protection. Using each of the proteins contained within the
combination plus an additional protein that was highly stimulatory
in the splenocyte assay (Figure 2; SP 0862), we immunized mice
intranasally with vaccines comprised of single proteins and CT. As
shown in Figure 4, SP2070 was highly protective (over 2 log
reduction in median density of colonization, p=0.005 vs. CT
control). Additionally, SP1534 and SP0862 conferred statistically
significant reduction in colonization compared with CT-immu-
nized controls (over 1 log reduction in median density of
colonization). Animals immunized with SP2092 were not protect-
ed, as predicted by the low IL-17A elicited by this protein in the
splenocytes stimulation assay.
Discussion
We present a sequential method that we used to identify
pneumococcal T cell antigens that, when administered as mucosal
vaccines with CT, elicit IL-17A responses and provide protection
against pneumococcal colonization. In particular, SP2070 was
highly protective in our model and SP0862 and SP1534 both
significantly reduced colonization.
In an effort to overcome the limitations of PCV-based
approaches, many investigators have explored several serotype-
independent approaches [5]. A protein subunit vaccine comprised
of antigens that are well expressed and conserved across the
majority of infecting serotypes is one such approach. Different
Figure 1. Size separation of fractions and stimulation of
splenocytes. A. SDS-PAGE of fractions was performed and gel was
silver-stained; shown here are the electrophoretic patterns of three
fractions eluted into the same chamber during different transverse
elutions. B. Results from stimulation of splenocytes from WCC
immunized mice (n=6) with equal concentrations of each fraction.
Supernatants were collected after 3 days of incubation and IL-17A
concentration in the supernatant was measured by ELISA. IL-17A values
are shown here, normalized to the DMEM-stimulated response of each
animal. Bars represent medians with interquartile range. WCC:
chloroform-inactivated pneumococcal whole cell antigen, 10 mg
protein/ml; WCCsup: soluble fraction of WCC, 7 mg protein/ml.
doi:10.1371/journal.pone.0043445.g001
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mococcal antigens, such as a genomic approach to identify
protective proteins that express a secretion signal [15], identifica-
tion of protective proteins from human antibody screening using
genomic scale antigenic fingerprinting [16] and proteomic
screening to identify TH17 dependent antigens [14]. Here, instead
of using a genomic-scale approach, we used a multi-step
biochemical approach; 1) preparative SDS PAGE to size separate
fractions of the immunogenic soluble compartment of a pneumo-
coccal whole cell antigen 2) screening of fractions for IL-17
stimulatory properties in vitro 3) mass spectrometry of stimulatory
fractions to identify comprising proteins and 4) identification of
protective TH-17 antigens in vivo. A similar approach has been
used to identify IFN-c stimulatory antigens in mycobacterium
Figure 2. Stimulation of splenocytes from immune mice with purified recombinant proteins. Mice (n=7–10) were intranasally immunized
with WCC and cholera toxin as described. Splenocytes from immunized mice were stimulated with 10 mg/ml of the indicated recombinant protein for
3 days, after which supernatants were harvested and assayed for IL-17A concentration. Values are normalized to the DMEM stimulated response for
each animal. Bars represent medians with interquartile ranges.
doi:10.1371/journal.pone.0043445.g002
Figure 3. Protection against colonization by intranasal immunization with a mixture of proteins. Mice were intranasally immunized with
a mixture (Protein mix) containing 4 mg of SP0435, SP1534, and SP2070 and 1 mg of cholera toxin (CT) as adjuvant; control mice received CT alone or
WCC with CT (WCV). Blood was obtained 3 weeks after last immunization and mice were challenged one week later with strain 0603. Density of
colonization was determined one week after challenge by quantifying pneumococcal carriage from nasal washes. (A) IL-17A production was
determined in vitro from whole blood stimulated with pneumococcal whole-cell antigen. (B) Mice immunized with the WCV or the protein mixture
were significantly protected against colonization compared to mice that received CT alone. Bars indicate median values and P values were
determined by Mann-Whitney U test compared to mice immunized with CT alone.
doi:10.1371/journal.pone.0043445.g003
TH17 Antigens in Soluble Pneumococcal Fractions
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which T-cell mediated immunity to infection is thought to play an
important role.
There are several advantages to such a non-genomic approach
to immunodominant antigen identification; namely, this method
eliminates the need to generate a comprehensive antigenic
expression library. The method used here can be completed
relatively quickly and identifies a small number of immunodomi-
nant bands each comprised of several proteins which can be
individually screened either in vitro or in vivo for immunogenic and
protective potential, respectively. A limitation of this approach as it
was implemented here was that the starting material (WCCsup)
represents only the soluble compartment of pneumococcal cellular
growth, and does not address the potential of proteins in the
nonsoluble compartment. Additionally, we did not evaluate
different concentrations of the individual proteins used in
splenocyte stimulations so it is conceivable that the optimal
stimulatory potential of any individual protein was not evaluated.
However, as all of the identified proteins were within a relatively
close molecular weight range (approximately 20–60 kDa) the
molar amount represented in each stimulation was not drastically
different.
We recognize that nasal mucosal cells such as nasal associated
lymphoid tissue (NALT) or draining lymph nodes may represent
more relevant immune cells than the splenocytes that were
examined in the present study. Indeed, we have previously
documented the presence of IL-17A response from nasal mucosal
cells of WCV immunized mice [10]. However, the use of nasal
mucosal tissue for screening of potential immunogens poses several
challenges. First, evaluation of nasal mucosal lymphocyte
responses to multiple antigens from individual mice is not feasible,
as the numbers of cells that we can obtain from such tissue are too
low; pooling of cells from multiple animals is required. To be able
to perform the number of stimulations carried out with each of the
fractions and proteins in this study, a prohibitively large number of
mice would have been required. Furthermore, IL-17A responses
from nasal mucosal tissue are almost 2-log lower than from
splenocytes [10], which may reduce our ability to discriminate
between stimulatory and non-stimulatory fractions and proteins.
For these reasons, we favored the use of splenocytes for IL-17A
screening assays.
Amongst the twelve antigens identified, one antigen SP1572
(also known as PppA), has been shown to be protective against
colonization and sepsis and was therefore not studied in this paper
[18,19]. When the four most IL-17A immunogenic antigens were
each separately used as mucosal vaccines with CT, three of them
conferred significant reduction in colonization compared with CT-
immunized animals. Of these, SP2070 has been identified from
the cell wall fraction as an immunodominant target for age-
dependent antibody responses in children’s sera but has not been
tested for protection against invasive disease [20]. When we
compared our list with the top TH17 antigens that our group in
collaboration with Genocea Biosciences and PATH identified
following proteomic screening [14], there was no overlap. Because
of differences between the two screens, it is perhaps not surprising
that the strongest hits in the more comprehensive screen may not
be the same as those identified here. The previous proteomic
screen identified TH17 antigens from the pneumococcal proteome
that stimulated robust IL-17A from CD4+ T cells of mice
immunized with a pneumococcal whole cell vaccine; in contrast,
here we identified TH17 antigens from a single predominant
protein band within an immunogenic fraction of the chloroform-
soluble fraction of a whole cell preparation. There are many
possible reasons why the results of the two screens differ, such as
differences in the proteins present in the chloroform-soluble
fraction vs. the most abundant proteins in the whole cell vaccine.
Additionally, the comprehensive screen relied on complex
statistical analyses for identification of a ‘‘hit,’’ criteria that were
not required for the screen presented here.
Since we are aiming to develop a pneumococcal vaccine to
provide serotype-independent immunity, it will be important to
test the efficacy of any of the protective proteins against strains of
diverse serotypes and/or multilocus sequence types (MLST). From
the identified panel of antigens, (initially consisting of 37 proteins)
we used several bioinformatic filters to further narrow the panel,
including the requirement for high sequence homology across all
sequenced pneumococcal strains. Of the 12 identified antigens, all
but 2 had $98% homology at the amino acid level with the 22
available sequenced strains; SP 1572 and SP2092 had 89% and
95% homology, respectively. Plans to test the ability of these
proteins to protect against strains of different serotypes and MLST
are underway.
Intranasal immunization with these antigens provides protection
against colonization, but such a route requires the use of an
adjuvant such as CT, which is not appropriate for human use. In
our experience, subcutaneous immunization of purified proteins
with aluminum hydroxide did not induce IL-17A production
unless proteins were introduced in a fusion conjugate construct
[21]. It is conceivable that development of a pneumococcal protein
subunit vaccine would contain several antigens and/or be
formulated with different or novel adjuvants, or perhaps as a
fusion-conjugate [21] to improve immunogenicity and facilitate
parenteral administration. Fusion conjugates comprised of the
proteins identified here with either pneumococcal cell wall
polysaccharide or Salmonella typhi Vi polysaccharide to provide
protection against pneumococcal and/or S. typhi diseases are
currently under investigation within our laboratory [22].
In conclusion, using this sequential method of size separation of
immunodominant fractions of the soluble compartment of a
pneumococcal whole cell preparation and mass spectrometry to
Figure 4. Immunization with individual proteins confers
protection against nasopharyngeal carriage. Mice were intrana-
sally immunized twice with 1 mg of cholera toxin alone (CT) or CT
combined with the proteins as indicated. Four weeks after the second
immunization, mice were intranasally challenged with strain 0603;
density of colonization was determined one week later. Bars indicate
median values and nasal colonization density was compared by the
Mann-Whitney U test.
doi:10.1371/journal.pone.0043445.g004
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stimulatory proteins tested in a colonization model were found to
be protective while the lowest IL-17A stimulatory protein
conferred no protection. The proteins identified with this method
may represent promising candidates for inclusion in a protein-
based pneumococcal vaccine.
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